CAPR (Capricor Therapeutics) Total Operating Expense: $119.93 Mil (TTM As of Mar. 2026)


CAPR Capricor Therapeutics Inc CAPR
37 GF Score
Price $26.41
GF Value $4.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics Total Operating Expense?

Capricor Therapeutics CAPR -13.03% 37 Total Operating Expense is $119.93 Mil as of Mar. 2026. GuruFocus rates CAPR with a GF Score™ of 37/100 and a GF Value™ of $4.87 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Capricor Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $36.77 Mil. Capricor Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $119.93 Mil.

Capricor Therapeutics Total Operating Expense Related Terms

Capricor Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Total Operating Expense Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.18 32.25 49.26 64.83 108.14

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.98 27.72 26.28 29.16 36.77
CAPR
37GF Score
Capricor Therapeutics Inc CAPR
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Capricor Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $119.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $119.93 Mil mean?
Capricor Therapeutics (CAPR) has a Total Operating Expense of $119.93 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' Total Operating Expense too high?
Capricor Therapeutics' current Total Operating Expense is $119.93 Mil. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Total Operating Expense compare to SNDX and SLS?
Capricor Therapeutics' Total Operating Expense of $119.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Capricor Therapeutics and its competitors. Capricor Therapeutics's current Total Operating Expense is $119.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $26.41 — trading 442.3% above its estimated fair value. The current Total Operating Expense is $119.93 Mil. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current Total Operating Expense is $119.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Capricor Therapeutics (CAPR) Overvalued in 2026?

Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued. The current stock price of $26.41 is trading 442.3% above its estimated GF Value™ of $4.87. GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.

Key valuation signals for CAPR:

  • Total Operating Expense: $119.93 Mil
  • GF Value™: $4.87 vs. price of $26.41 (442.3% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Capricor Therapeutics Business Description

Other Exchanges 4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score

Get the complete analysis for CAPR

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.41
Price
$4.87
GF Value